[Clinical and hemostatic evaluation of curantyl in hypertensives].
Curantyl supplemented to the multimodality therapy for patients with Stage II essential hypertension with uncomplicated events or complicated by hypertensive crisis was ascertained to lower the intensity of intravascular blood microcoagulation due to its modifying effect on the procoagulative and thrombocytic links of hemostasis and blood fibrinolytic activity. The drug exerted no marked positive action on clinical manifestations of the disease and caused no significant changes in the parameters of hemostatic procoagulative and thrombocytic links and blood fibrinolytic activity.
Ena
Ia M
IaM
Didkovskaia
L A
LA
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects; D004176:Dipyridamole / Q000627:therapeutic use*; D004341:Drug Evaluation; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged
D004176:Dipyridamole
Kliniko-gemostaziologicheskaia otsenka kurantila u bol'nykh gipertonicheskoĭ bolezn'iu.